<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This study evaluates the prognostic value of <z:e sem="disease" ids="C0242596" disease_type="Neoplastic Process" abbrv="MRD">minimal residual disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e>) monitoring by multiparametric flow cytometry in 41 patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> undergoing allogeneic transplantation </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> assessment after transplant (day +100) allowed to discriminate different risk populations, being the most significant cut-off value for outcome level of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> &lt; or &gt; or = 10(-3) </plain></SENT>
<SENT sid="2" pm="."><plain>Outcome was significantly better among patients with low (&lt;10(-3)) versus high (&gt; or = 10(-3)) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> at day +100 after transplant </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, overall survival was 73% versus 25% at 4 years among patients with low versus high <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> at day +100 after transplant (P = 0.002); 74% of patients with low <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> were event free at 4 years as compared to 17% among patients with high <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> (P = 0.01) </plain></SENT>
<SENT sid="4" pm="."><plain>In multivariate analysis, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> value as well as <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD significantly influenced outcome </plain></SENT>
<SENT sid="5" pm="."><plain>In conclusion, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MRD</z:e> monitoring early post-transplant is an important tool for outcome prediction and should be considered in decision making after allogeneic transplantation </plain></SENT>
</text></document>